Certified by Founder Lodge 
                                        
                                        Longwood Fund
 
                                                 United States  -  Boston, MA 
                                             INVESTOR 
                                            
                                                                                    1 Disclosed Funding Rounds $65,333,745
                                            11 Participating Investments
- 
                                                Operating Status 
                                                
Active
 - 
                                                Last Funding Type 
                                                
Seed
 - 
                                                Company Type 
                                                
For Profit
 - Website
 - Contact
 - Social Links
 
                                            Longwood creates and invests in science-based companies that develop novel solutions for important medical problems.
                                        
                                        
                                        
                                                                                
                                        
                                        
                                        
                                        
                                                                                
                                        | Company | Date | Round | Raised | 
|---|---|---|---|
   Newleos Therapeutics | 
                                                            February, 20 ,2025 | Series A | $93,500,000 | 
   Be Biopharma | 
                                                            October, 23 ,2024 | Unknown | $82,000,000 | 
   AAVantgarde Bio | 
                                                            June, 07 ,2023 | Series A | $65,333,745 | 
   Solu Therapeutics | 
                                                            August, 01 ,2023 | Seed | $31,000,000 | 
   Sitryx | 
                                                            September, 28 ,2023 | Unknown | $39,500,000 | 
   Tome Biosciences | 
                                                            December, 14 ,2023 | Series B | $213,000,000 | 
   Engrail Therapeutics | 
                                                            March, 20 ,2024 | Series B | $157,000,000 | 
   Be Biopharma | 
                                                            October, 23 ,2024 | Unknown | $82,000,000 | 
   Newleos Therapeutics | 
                                                            February, 20 ,2025 | Series A | $93,500,000 | 
   Avenzo Therapeutics | 
                                                            September, 23 ,2025 | Series B | $60,000,000 | 
   Crystalys Therapeutics | 
                                                            October, 01 ,2025 | Series A | $205,000,000 | 
                                                
  Newleos Therapeutics
  Be Biopharma
  AAVantgarde Bio
  Solu Therapeutics
  Sitryx
  Tome Biosciences
  Engrail Therapeutics
  Avenzo Therapeutics
  Crystalys Therapeutics
Cherry Ventures
 
                                            
Blue Bear Capital
Slow Ventures
Climate Capital
Eniac Ventures
                                                                        
                                Helex |  $3,500,000  | (Nov 4, 2025)
                                                                        
                                xMEMS |  $21,000,000  | (Nov 4, 2025)
                                                                        
                                catalyx space |  $5,400,000  | (Nov 4, 2025)
                                                                        
                                Cephia AI |  $4,000,000  | (Nov 4, 2025)
                                                                        
                                Ornn |  $5,700,000  | (Nov 4, 2025)